Second Genome Revenue and Competitors
Estimated Revenue & Valuation
- Second Genome's estimated annual revenue is currently $697.5k per year.
- Second Genome's estimated revenue per employee is $77,500
- Second Genome's total funding is $62.5M.
Employee Data
- Second Genome has 9 Employees.
- Second Genome grew their employee count by -10% last year.
Second Genome's People
Name | Title | Email/Phone |
---|---|---|
1 | Director | Reveal Email/Phone |
2 | Director | Reveal Email/Phone |
3 | Chief Scientific Officer | Reveal Email/Phone |
4 | Senior Research Associate | Reveal Email/Phone |
5 | Cloud System Administrator | Reveal Email/Phone |
6 | Research Associate II | Reveal Email/Phone |
7 | Scientist II | Reveal Email/Phone |
Second Genome Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $6M | 39 | -9% | N/A | N/A |
What Is Second Genome?
Second Genome, a venture-backed Bay Area based life sciences company, is committed to improving the quality of human health through microbiome-based personalized medicine. Founded in 2009 by leading experts in microbial research, molecular diagnostics, and biotechnology R&D, Second Genome is using its proprietary Microbiome Signature Discovery platform to generate novel insights relating the microbiome with a wide range of human health disorders. Working with academic and commercial collaborators, Second Genome is developing novel diagnostic tools and therapies for unmet needs in gastrointestinal disorders
keywords:N/A$62.5M
Total Funding
9
Number of Employees
$697.5k
Revenue (est)
-10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Second Genome News
We use the latest primary and secondary research techniques to compile this ... Tau Pharmaceuticals, Pfizer Inc., Second Genome, AbbVie Inc.
... Market by 2029 | Vedanta, Seres Therapeutics, Second Genome ... The research is carried out on primary and secondary statistics sources...
Second Genome is a biotechnology company that leverages its proprietary technology-enabled platform to discover and develop transformational...
Second Genome, a South San Francisco, California-based biopharmaceutical company, raised $8.4m in Series B financing. SR One made – the corporate venture capital arm of GlaxoSmithKline – the investment, which brought the total Series B funding round to $51m. It joined Pfizer Venture Investments ...
Second Genome, Inc., a South San Francisco, CA-based biopharmaceutical company developing novel medicines through innovative microbiome science, closed a $42.6m Series B funding. The round was co-led by Pfizer Venture Investments and Roche Venture Fund with participation from new investors Digi ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.1M | 9 | 0% | N/A |
#2 | $0.7M | 9 | N/A | N/A |
#3 | $0.5M | 9 | 50% | N/A |
#4 | $0.9M | 10 | -37% | N/A |
#5 | $0.9M | 10 | N/A | N/A |